Physician profile
Jamison Eugene Strahan
NPI 1578600839
$2,905.66
in general payments reported to CMS, 2019-2025
22 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.96 · 2020: $106 · 2021: $131 · 2022: $469 · 2023: $724 · 2024: $616 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $458.68 | 2022-2025 | |
| Abbvie INC. | $451.35 | 2022-2025 | Rinvoq |
| Janssen Biotech, INC. | $222.99 | 2023-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $203.79 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $198.80 | 2022-2024 | Levulan Kerastick, Winlevi |
| Galderma Laboratories, L.P. | $191.10 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $172.70 | 2019-2023 | |
| Amgen INC. | $162.54 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $154.06 | 2022-2024 | Vtama |
| Pfizer INC. | $135.61 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $130.96 | 2022 | |
| Almirall LLC | $100.94 | 2019-2025 | Klisyri |
| Strata Skin Sciences, INC. | $77.34 | 2022 | |
| Leo Pharma INC. | $65.94 | 2022-2025 | Anzupgo, Adbry |
| Incyte Corporation | $60.74 | 2022-2025 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.31 | 2025 | Dupixent |
| Helsinn Therapeutics (U.S.), INC. | $20.29 | 2023 | Valchlor |
| Organogenesis INC. | $18.35 | 2023 | Puraply |
| Mallinckrodt Hospital Products INC. | $16.36 | 2025 | Acthar |
| Vyne Pharmaceuticals INC. | $14.50 | 2020 | |
| Kerecis Limited | $13.42 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Verrica Pharmaceuticals INC. | $12.89 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Strahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.